In the movement towards individualized treatment regimens, Rothenberg et al. validate XELOX as another available systemic therapy for patients being treated with second-line treatment for metastatic colorectal cancer. This paper adds to a growing body of data in the first-line and second-line setting that confirms the noninferiority of oral fluoropyrimidine-containing regimens.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rothenberg, M. et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann. Oncol. 19, 1720–1726 (2008).
Cassidy, J. et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J. Clin. Oncol. 26, 2006–2012 (2008).
Ducreux, M. et al. Efficacy and safety findings from a randomized phase III study of capecitabine (X) and oxaliplatin (O) (XELOX) vs infusional 5-FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC) [Abstract]. ASCO Meeting Abstracts 25, 4029 (2007).
Arkenau, H. T. et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J. Clin. Oncol. 26, 5910–5917 (2008).
Haller, D. G. et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J. Clin. Oncol. 26, 2118–2123 (2008).
Arkenau, H. et al. Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clin. Colorectal Cancer 7, 60–64 (2008).
Schmoll, H. J. et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J. Clin. Oncol. 25, 102–109 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Teitelbaum, U., Haller, D. Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer. Nat Rev Clin Oncol 6, 250–251 (2009). https://doi.org/10.1038/nrclinonc.2009.46
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.46
